Zepbound now offered in KwikPen with a month's worth of doses

Eli Lilly introduced a KwikPen multi-dose device for Zepbound that holds four weekly doses and is being sold on LillyDirect starting at $299 per month after an FDA label expansion approved the device.

Eli Lilly has launched a multi-dose KwikPen form of its obesity treatment Zepbound that contains a month's worth of doses in a single pen. The company said the pen holds four weekly doses and is available to cash-paying patients through its LillyDirect website. Prices for the lowest dose level start at $299 per month on LillyDirect. Lilly said the Food and Drug Administration approved a label expansion to allow the multi-dose device. Key details: - The KwikPen contains four weekly doses, allowing one pen to cover a month's supply. - Cash-paying patients can purchase the multi-dose device on LillyDirect, with the lowest dose level priced from $299 per month. - Until now, patients typically used a different single-dose autoinjector each week or single-dose vials that require drawing medication into a syringe. - Lilly announced that the FDA approved a label expansion to include the multi-dose KwikPen for Zepbound. - The KwikPen is already used for other Lilly medicines, including the diabetes drug Mounjaro, the company said. - The article reports Zepbound generated $4.2 billion in U.S. revenue in the company's fourth quarter, a 122% increase from the prior year. Summary: Lilly describes the KwikPen as a new delivery option that may reduce the number of devices patients use each month and that will be offered through LillyDirect. Undetermined at this time.